Kuan-Ching Huang

Dr. Kuan-Ching Huang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Kuan-Ching HuangKuan-Ching Huang
Kuan-Ching Huang
JCJen-Yu Cheng
Jen-Yu Cheng
CCChung-Shih Chen
Chung-Shih Chen
CWChong-Jong Wang
Chong-Jong Wang
ENG-YEN HUANGENG-YEN HUANG
ENG-YEN HUANG
Objectives: In patients undergoing a radical hysterectomy, uterine corpus invasion worsens cervical cancer prognosis. However, the prognostic role of the invasion in locally advanced stages remains elusive. Due to the inadequacy of typical corpus biopsies, corpus invasion is diagnosed using magnetic resonance imaging (MRI). In this study, we investigated the prognostic role of MRI-detected uterine corpus invasion in patients undergoing radiotherapy for cervical cancer. Methods: This retrospective analysis involved 259 patients without extrapelvic metastases, diagnosed with FIGO 2009 stages IB–IVA cervical carcinoma from January 2011 to December 2020. The corpus invasion extent was classified as exocervical-confined (group 1), endocervical (group 2), or uterine corpus invasion (group 3). The rates of overall survival, cancer-specific survival, locoregional recurrence, para-aortic lymph node recurrence, and extrapelvic metastases after pelvic radiotherapy were analyzed. Kaplan–Meier and Cox regression analyses were used to determine recurrence-associated risks. Optimal risk stratification was predicted using a receiver operating characteristic curve with the area under the curve. Results: Groups 1, 2, and 3 included 66.0%, 18.9%, and 15.1% of patients, respectively. The 5-year para-aortic lymph node recurrence rates were 6.3%, 17.2%, and 34.2% (p < 0.001). Uterine corpus invasion was an independent factor for overall survival, cancer-specific survival, locoregional recurrence, extrapelvic metastases, and para-aortic lymph node recurrence. Including uterine corpus invasion in the risk stratification led to higher areas under the curve for overall survival, cancer-specific survival, locoregional recurrence, extrapelvic metastases, and para-aortic lymph node recurrence than using single parameters. Conclusions: In cervical cancer, following pelvic radiotherapy, uterine corpus invasion is a significant prognostic factor. More-aggressive treatments such as extended-field radiotherapy, adjuvant chemotherapy, and immune checkpoint inhibitors as an alternative to standard pelvic radiotherapy with concurrent chemotherapy may be considered in these patients.

31 October 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
Kuan-Ching HuangKuan-Ching Huang
Kuan-Ching Huang
MKMing-Chun Kuo
Ming-Chun Kuo
PLPei-Hang Lee
Pei-Hang Lee
THTzu-Ting Huang
Tzu-Ting Huang
Direct hepatic invasion is an uncommon presentation of esophageal squamous cell carcinoma (ESCC), and evidence guiding chemoradiotherapy in this setting is limited. A 59-year-old man presented with middle-to-lower thoracic ESCC extending through the esophagogastric junction and gastric cardia, with direct hepatic invasion. Extensive regional nodal disease and a solitary right supraclavicular nonregional nodal metastasis supported cT4bN3M1 stage IVB disease, with high PD-L1 expression. The patient received curative-intent radiotherapy with concurrent cisplatin, paclitaxel, and nivolumab. The planned radiotherapy dose was 50.4 Gy in 28 fractions to the esophageal and regional lymph node volume, with a simultaneous integrated boost to the gross tumor and gross lymph nodes to 56 Gy in 28 fractions, followed by a sequential boost to the supraclavicular lymph node to a total 66 Gy in 33 fractions. After the 25th fraction, computed tomography results demonstrated contained tumor–gastric fistulization without pneumoperitoneum; therefore, the remaining three fractions to the esophageal and regional volumes were not delivered. The delivered doses were 45 Gy to these volumes and 50 Gy to the gross disease, each in 25 fractions. A conservative treatment strategy was initiated, including withholding oral intake, administering intravenous antimicrobial therapy, and continuing jejunal enteral feeding. Maintenance nivolumab with infusional 5-fluorouracil was continued for more than three years as an individualized strategy not based on an established prospective trial regimen. With pathological diagnosis designated as Month 0, positron emission tomography/computed tomography demonstrated complete metabolic response at Month 4, with no recurrent or metastatic disease on follow-up examinations through Month 44 during ongoing maintenance therapy. This case highlights durable disease control after immunotherapy-integrated chemoradiotherapy in advanced ESCC with initial direct liver invasion and the value of individualized treatment adaptation when tumor–gastric fistulization develops.